Glucagon - Novo Nordisk

Drug Profile

Glucagon - Novo Nordisk

Alternative Names: GlucaGen

Latest Information Update: 23 Jul 2014

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypoglycaemia

Most Recent Events

  • 15 Jul 2014 Bedford Laboratories has been acquired by Hikma Pharmaceuticals
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 24 Sep 2009 Registered for Hypoglycaemia in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top